Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY Extension trial of oral cladribine in relapsing-remitting multiple sclerosis
NL-OMON32113Phase 3Active, not recruiting
- Sponsor
- IATEC
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Oral cladribine with Placebo (2 arms). Primary endpoints: Safety and tolerability of oral cladribine and QTc interval effect. Started Apr 2009; status: active, not recruiting.
02
Drugs
cladribine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON32113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32113.